Understand drug prices
Why are drug prices so expensive?
Prescription drug pricing in the United States involves more parties than most people realise: manufacturers, wholesalers, pharmacy benefit managers, insurers, employers, pharmacies and government programs. Each one affects what you end up paying. This guide explains the main forces at work, and why the price at the pharmacy counter can be many times what the pharmacy paid for the medicine.
Key takeaways
- Manufacturers set list prices for brand drugs, but few buyers pay the full list price.
- Pharmacy benefit managers (PBMs) negotiate rebates that are often hidden from patients.
- Coinsurance and deductibles are often based on the higher list price, not the net price.
- Pharmacies set their own "usual and customary" cash prices, which can be far above cost.
- Patents and exclusivity keep competition away from new brand drugs for years.
- Generic prices are usually low, but can jump when there are few makers or a shortage.
Who sets the price?
There is no single price for a drug. There are several prices, each used by different parties:
- List price (WAC). The Wholesale Acquisition Cost is the manufacturer's published price to wholesalers. It is the starting point most people mean when they talk about a drug's price.
- Acquisition cost. What a pharmacy actually pays its wholesaler. For brands this is usually close to list; for generics it is often far below anything you would guess. NADAC measures this - see what is NADAC.
- Net price. What the manufacturer receives after rebates and discounts to PBMs, insurers and government programs. It is usually confidential.
- Reimbursement. What an insurance plan or PBM pays the pharmacy for a prescription.
- Usual and customary price. The pharmacy's own cash price for people paying without insurance.
The gaps between these numbers are where much of the confusion, and much of the cost, comes from.
List prices and brand-name drugs
For a new brand-name drug, the manufacturer sets the list price. Companies point to the cost of research and development, clinical trials and failed projects. Critics point out that prices in the US are typically much higher than in other wealthy countries, where governments negotiate directly. Whatever the reason, US list prices for brand drugs have historically risen year after year, and many patients feel those increases directly.
PBMs and rebates
Pharmacy benefit managers run the prescription side of most health plans. They build the formulary (the list of covered drugs), set up pharmacy networks, process claims and negotiate with manufacturers. In return for placing a brand drug in a favourable position on a formulary, a manufacturer may pay the PBM or plan a rebate - sometimes a large share of the list price.
Rebates can lower overall plan costs, but they create some awkward incentives:
- A drug with a high list price and a big rebate may be preferred over one with a lower list price and a small rebate.
- Rebates are usually paid to the plan, not passed directly to the patient at the counter.
- If your coinsurance or deductible is based on list price, you may pay a share of a price that nobody in the system actually pays.
This is one reason why someone with insurance can sometimes pay more at the counter than a cash customer. Some states and employers have pushed for rebates to be shared at the point of sale, and the rules continue to evolve.
Why the cash price can be far above cost
When you pay without insurance, you usually pay the pharmacy's usual and customary (U&C) price unless you ask for something lower. Pharmacies have reasons to set U&C prices high. In some insurance contracts, the pharmacy's reimbursement is the lower of the plan's rate or its U&C price, so a low U&C price could reduce what it gets paid on insured claims. The result is that the "sticker price" for a cash customer can be many times the drug's acquisition cost, especially for cheap generics.
That does not mean every pharmacy is overcharging. Pharmacies have real costs, and margins on many insured prescriptions are thin. But it does mean that a cash quote is often a starting point, not a final figure. Our guide on how to tell if your drug price is fair shows how to compare a quote with a fair benchmark.
Free toolIs my drug price fair? Check any quotePatents and exclusivity
New drugs are protected from direct competition for a period by patents and by FDA exclusivity rules. During that time, only the brand can be sold, and there is little price pressure. Companies may also obtain additional patents on new formulations, dosing devices or manufacturing methods, which can extend the period before generics arrive. Patent challenges and legal settlements often decide the real timing. Read when will a generic be available for how this works, and see our upcoming generics tracker.
Competition, or the lack of it
Once generics launch, prices usually fall, and they tend to fall further as more manufacturers join. But competition is not guaranteed. Some generics are made by only one or two companies. Products that are hard to make, such as certain injectables, inhalers and complex formulations, may attract few competitors. Biologic drugs face competition from biosimilars, which are more expensive to develop than standard generics and have taken longer to gain market share.
When a market has few sellers, a single company leaving or raising prices can have a large effect. You can see these movements in the weekly data on our price changes page.
Shortages and supply problems
Very low prices can cause problems of their own. Some older generic drugs sell for so little that manufacturers have limited incentive to invest in their factories, and when a plant has a quality problem, there may be no one ready to replace its output. Shortages follow, and prices for the remaining supply can rise. Our guide to drug shortages covers why they happen and what patients can do.
What is changing
Several changes are reshaping the picture:
- Medicare negotiation. Under the Inflation Reduction Act, Medicare now negotiates prices for some high-cost drugs, with the first negotiated prices taking effect in January 2026. See Medicare drug price negotiation explained.
- Out-of-pocket caps. Medicare Part D now has an annual cap on out-of-pocket drug costs, and insulin costs for Medicare enrollees are capped at $35 a month.
- Cost-plus pharmacies. Some pharmacies now publish transparent pricing based on acquisition cost plus a set markup and fee.
- PBM scrutiny. Federal and state regulators have been examining PBM practices, and rules in this area continue to change.
What you can do about it
- Look up your drug's acquisition cost and fair cash price on FairPill.
- If you have insurance, compare your copay with the cash price - occasionally cash is cheaper.
- Ask your prescriber whether a generic or lower-cost alternative is appropriate for you.
- Compare cash prices at several pharmacies, including cost-plus options.
- For brand drugs, check manufacturer savings and patient assistance programs.
Real-world prices help make the system more transparent. If you have paid for a prescription recently, you can share what you paid anonymously so others can see how counter prices compare with costs.
This guide is general information, not medical or financial advice. Talk to your pharmacist or prescriber about your own medicines.
Questions about this guide
No comments yet. Questions, tips, what worked for you - start the conversation.